Fresenius Kabi looks set to wait until the middle of the next decade to launch its proposed US generic version of Heron Therapeutics’ Cinvanti (aprepitant) injectable emulsion for chemotherapy-induced nausea and vomiting, after falling to the originator in patent-infringement proceedings.
The US District Court for the District of Delaware has held that Kabi’s aprepitant abbreviated new drug application product infringes...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?